Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

257
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
257
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

8.3K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.3K
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

176
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
176
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

11.8K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.8K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Normal thromboelastography with a markedly prolonged activated partial thromboplastin time in severe prekallikrein deficiency: Implications for perioperative hemostatic assessment.

Transfusion·2026
Same author

A global survey of blood transfusion practices for patients with sickle cell disease.

Transfusion·2026
Same author

Alpha-Gal Syndrome: Unrecognized Risks of a Tick-Bite-Associated Allergy in Transplantation and Cellular Therapy.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

AABB survey on directed blood donation practices.

Transfusion·2026
Same author

Cost analysis considerations for red blood cell matching to mitigate alloimmunization in patients with sickle cell disease.

Transfusion·2026
Same author

A survey of transfusion support strategies for passenger lymphocyte syndrome in minor ABO-mismatched allogeneic hematopoietic stem cell transplantation.

Transfusion·2026

Video Experimental Relacionado

Updated: Jan 7, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.2K

Suplementación con Factor XIII en la Hemorragia Posparto: De la Razón Biológica a la Implementación Clínica

Jeremy W Jacobs1,2, Elizabeth A Abels3, Brian D Adkins4

  • 1Department of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, Tennessee, USA.

American journal of hematology
|December 31, 2025
PubMed
Resumen

La suplementación temprana con Factor XIII puede reducir la mortalidad materna por hemorragia posparto (HPP). Este estudio investiga el FXIII

Palabras clave:
hemorragia pospartofactor XIIIcoagulaciónmedicina traslacionalobstetriciahematología

Más Videos Relacionados

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.7K
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

14.3K

Videos de Experimentos Relacionados

Last Updated: Jan 7, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.2K
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.7K
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

14.3K

Área de la Ciencia:

  • Obstetricia y Ginecología
  • Hematología
  • Medicina Traslacional

Sus antecedentes:

  • La hemorragia posparto (HPP) es una de las principales causas de muerte materna prevenible.
  • Las intervenciones estándar y los ensayos con fibrinógeno han mostrado un éxito limitado en la reducción de la mortalidad relacionada con la HPP.
  • La actividad del Factor XIII de Coagulación (FXIII) disminuye durante el embarazo y la HPP, lo que sugiere un papel en la hemostasia.

Objetivo del estudio:

  • Evaluar la eficacia de la suplementación temprana con FXIII en el manejo de la HPP.
  • Investigar el FXIII como un posible agente terapéutico para la HPP.
  • Abordar la necesidad insatisfecha de mejorar las intervenciones para la HPP.

Principales métodos:

  • El ensayo SWIFT (NCT06481995) es el primer ensayo controlado aleatorizado sobre la suplementación temprana con FXIII en la HPP.
  • Los estudios observacionales indican que el bajo nivel de FXIII anteparto predice el riesgo de sangrado.
  • Los estudios ex vivo demuestran que la suplementación con FXIII restaura la firmeza del coágulo.

Principales resultados:

  • Los datos observacionales sugieren que el bajo nivel de FXIII se asocia con un mayor riesgo de sangrado.
  • Los experimentos ex vivo muestran que la suplementación con FXIII mejora la estabilidad del coágulo.
  • El ensayo SWIFT está en curso, evaluando la administración temprana de FXIII en pacientes con HPP.

Conclusiones:

  • El FXIII desempeña un papel crítico en la estabilización de los coágulos sanguíneos.
  • La suplementación temprana con FXIII es una estrategia prometedora para mejorar los resultados de la HPP.
  • Abordar los desafíos de implementación es crucial para la adopción exitosa de la terapia con FXIII en el manejo de la HPP.